An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

A common artificial sweetener may trigger insulin spikes that lead to the build up of fatty plaques in the arteries, ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Discover how this diabetes drug is revolutionizing heart health. Learn about its surprising benefits in reducing cardiovascular risks and mortality.

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

More than 830 million people worldwide have diabetes—a chronic, debilitating disease. But experts say it’s possible to recover with a few proven lifestyle changes.

About 90% of U.S. adults meet the criteria for a newly recognized syndrome that comes from a combination of heart disease, ...

Driven by rising rates of high blood pressure, obesity, and other key risk factors, heart disease remains the leading cause ...

Blood pressure. Having both diabetes and high blood pressure dramatically increases heart disease risk. Triglycerides and low ...

While conducting the study, the researchers tracked data from more than 10,000 patients who presented with type 2 diabetes, ...

The deaths are also partly the result of medical successes: People are living longer, and more people are surviving heart ...